Volume 3.41 | Oct 26

Prostate Cell News 3.41 October 26, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Recruitment of NCOR1 to VDR Target Genes Is Enhanced in Prostate Cancer Cells and Associates with Altered DNA Methylation Patterns
The authors investigated transcriptional distortion in prostate cancer cells. The actions of the vitamin D receptor (VDR) and how epigenetic events driven by co-repressor binding and CpG methylation lead to aberrant gene expression were investigated. [Carcinogenesis] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Klf4 Transcription Factor Is Expressed in the Cytoplasm of Prostate Cancer Cells
Investigators comparatively addressed the expression of genes encoding putative stemness regulators including c-Myc, Klf4, Nanog, Oct4A and Sox2 genes in benign prostatic hyperplasia and prostate cancer. [Eur J Cancer] Abstract

Antioxidant Treatment Promotes Prostate Epithelial Proliferation in Nkx3.1 Mutant Mice
Loss of expression of the homeobox transcription factor NKX3.1 in the prostate is frequently associated with human prostate cancer. While the mechanisms by which Nkx3.1 loss promotes prostate tumorigenicity are not completely understood, published data have suggested that elevated reactive oxygen species associated with Nkx3.1 loss may be a causative factor. The authors tested this hypothesis by treating Nkx3.1 mutant mice with the antioxidant N-acetylcysteine for 13 weeks post-weaning. [PLoS One] Full Article

Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways
Researchers discovered that quercetin reduced the cell viability and induced apoptosis in prostate cancer cells, which were correlated with the downregulation of AKT, mTOR and P70S6K expressions. [PLoS One] Full Article

Interleukin-27 Expression Modifies Prostate Cancer Cell Crosstalk with Bone and Immune Cells
Prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment amplifies tumor growth. Scientists explored the potential of a novel cytokine, interleukin-27 (IL-27), for inhibiting this malignant crosstalk, and examined the effect of autocrine IL-27 on prostate cancer cell gene expression, as well as the effect of paracrine IL-27 on gene expression in bone and T cells. [J Cell Physiol] Abstract

Vorinostat and Bortezomib Synergistically Cause Ubiquitinated Protein Accumulation in Prostate Cancer Cells
Researchers investigated whether the histone deacetylase inhibitor vorinostat and the proteasome inhibitor bortezomib would synergistically cause the accumulation of ubiquitinated proteins in prostate cancer cells. [J Urol] Abstract

GRP78-Targeted Nanotherapy Against Castrate-Resistant Prostate Cancer Cells Expressing Membrane GRP78
The authors developed anti-KDEL functionalized polymeric nanoparticles loaded with paclitaxel to specifically target prostate cancer cells expressing glucose-regulated protein 78 (GRP78). [Target Oncol] Abstract

Serum Testosterone Plays an Important Role in the Metastatic Ability of Castration Resistant Prostate Cancer
Investigators aimed to determine the role of testosterone in the formation of metastases of castration resistant prostate cancer in both in vitro and in vivo settings. [World J Urol] Abstract | Full Article

Wedelolactone, a Medicinal Plant-Derived Coumestan, Induces Caspase-Dependent Apoptosis in Prostate Cancer Cells via Downregulation of Protein Kinase Cε without Inhibiting Akt
Wedelolactone (WDL) is known to inhibit 5-lipoxygenase activity in neutrophils. However, its effect on apoptosis in prostate cancer cells has not been addressed. Researchers tested the effects of WDL on human prostate cancer cells in vitro. They observed that WDL kills both androgen-sensitive as well as androgen-independent prostate cancer cells in a dose-dependent manner by dramatically inducing apoptosis. [Int J Oncol] Abstract

CLINICAL RESEARCH

The Impact of Dose-Escalated Radiotherapy plus Androgen Deprivation for Prostate Cancer Using Two Linked Nomograms
The authors designed a model to estimate the results of various doses of radiotherapy combined with various durations of androgen-deprivation therapy. [Cancer] Abstract

Frequency of Brain Metastases from Prostate Cancer: An 18-Year Single-Institution Experience
Researchers compared the incidence of brain metastases in the pre- and post-docetaxel era in a single institution in which all oncological patients are referred to one radiotherapy and one medical oncology department. [J Neurooncol] Full Article

Ready Sep Go: Request a Free Cell Isolation Wallchart

REVIEWS
Characterization of Tumor Differentiation Factor (TDF) and Its Receptor
The authors review the current advances on TDF, with particular focus on the structural investigation of its receptor and on its functional effects on breast and prostate cells. [Cell Mol Life Sci]
Abstract
INDUSTRY NEWS

UB Biosciences Incubator Welcomes First Companies
The University at Buffalo (UB) Biosciences Incubator has selected its first tenants: AccuTheranostics, AndroBioSys and Ceno Technologies, three companies that will benefit from the facility’s location at UB’s Clinical and Translational Research Center on the Buffalo Niagara Medical Campus. AndroBioSys, the brainchild of two Roswell Park Cancer Institute researchers, is developing novel ways to detect, image and treat early prostate cancer. [University at Buffalo] Press Release


Association Establishes the AABB Center for Cellular Therapies
AABB (formerly the American Association of Blood Banks) has established the AABB Center for Cellular Therapies, a functional unit within AABB that will focus on activities designed to foster patient safety and responsible innovation in the cellular therapy and regenerative medicine field. [AABB] Press Release


Astellas Launches Gonax® (Degarelix Acetate) for Subcutaneous Injection in Japan for Treating Prostate Cancer
Astellas Pharma Inc. announced the launch of Gonax® for Subcutaneous Injection in Japan for the indication of prostate cancer. Gonax is a gonadotrophin-releasing hormone-receptor blocker with a subcutaneously injectable formulation. [Astellas Pharma Inc.] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Workshop on Approval and Commercialization of Advanced Therapy Medicinal Products in Europe
November 15, 2012
Berlin, Germany

Visit
our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)


Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)


Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Postdoctoral Position – Prostate Cancer Metastasis (Lund University)

Postdoctoral Position – Prostate Cancer (Sunnybrook Research Institute)

Research Associate – Quality Assurance (University of California)

Postdoctoral Position – Prostate Tumor Mouse Models (Medical University of South Carolina)

Postdoctoral Position – Advanced Prostate Cancer Investigations (University of Texas Southwestern Medical Center)

Postdoctoral Position – Fluorescent Protein Technology/Cloning (State University of Campinas)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)



Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us